Innoviva Income from Continuous Operations 2010-2024 | INVA
Innoviva income from continuous operations from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Innoviva Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$180 |
| 2022 |
$220 |
| 2021 |
$369 |
| 2020 |
$294 |
| 2019 |
$191 |
| 2018 |
$406 |
| 2017 |
$134 |
| 2016 |
$60 |
| 2015 |
$-19 |
| 2014 |
$-74 |
| 2013 |
$-31 |
| 2012 |
$-31 |
| 2011 |
$-115 |
| 2010 |
$-84 |
| 2009 |
$-85 |
Innoviva Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$-35 |
| 2024-03-31 |
$37 |
| 2023-12-31 |
$62 |
| 2023-09-30 |
$82 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$35 |
| 2022-12-31 |
$-68 |
| 2022-09-30 |
$229 |
| 2022-06-30 |
$21 |
| 2022-03-31 |
$38 |
| 2021-12-31 |
$46 |
| 2021-09-30 |
$103 |
| 2021-06-30 |
$111 |
| 2021-03-31 |
$110 |
| 2020-12-31 |
$75 |
| 2020-09-30 |
$42 |
| 2020-06-30 |
$98 |
| 2020-03-31 |
$79 |
| 2019-12-31 |
$58 |
| 2019-09-30 |
$47 |
| 2019-06-30 |
$46 |
| 2019-03-31 |
$40 |
| 2018-12-31 |
$269 |
| 2018-09-30 |
$50 |
| 2018-06-30 |
$57 |
| 2018-03-31 |
$30 |
| 2017-12-31 |
$59 |
| 2017-09-30 |
$24 |
| 2017-06-30 |
$35 |
| 2017-03-31 |
$17 |
| 2016-12-31 |
$25 |
| 2016-09-30 |
$15 |
| 2016-06-30 |
$15 |
| 2016-03-31 |
$4 |
| 2015-12-31 |
$4 |
| 2015-09-30 |
$-5 |
| 2015-06-30 |
$-8 |
| 2015-03-31 |
$-11 |
| 2014-12-31 |
$-16 |
| 2014-09-30 |
$-21 |
| 2014-06-30 |
$-20 |
| 2014-03-31 |
$-16 |
| 2013-12-31 |
$18 |
| 2013-09-30 |
$-9 |
| 2013-06-30 |
$-2 |
| 2013-03-31 |
$-37 |
| 2012-12-31 |
$-31 |
| 2012-09-30 |
$-35 |
| 2012-06-30 |
$-37 |
| 2012-03-31 |
$85 |
| 2011-12-31 |
$-37 |
| 2011-09-30 |
$-31 |
| 2011-06-30 |
$-25 |
| 2011-03-31 |
$-23 |
| 2010-12-31 |
$-19 |
| 2010-09-30 |
$-21 |
| 2010-06-30 |
$-21 |
| 2010-03-31 |
$-23 |
| 2009-12-31 |
$-22 |
| 2009-09-30 |
$-22 |
| 2009-06-30 |
$-22 |
| 2009-03-31 |
$-19 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.222B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
